7th CB1, CB2 and Cannabinoid Drug Development Summit

As drug developers continue to utilize the expedited FDA regulatory pathway available for CBD, alongside a growing interest in the therapeutic benefits and regulatory approval of novel cannabinoids, the cannabinoid drug development landscape is rapidly evolving. Additionally, innovative preclinical candidates targeting CB1 and CB2 receptors are advancing through the pipeline, as developers aim to secure regulatory approval for treatments addressing weight management, pain, neurological conditions, and more. The field continues to grow, with both phytocannabinoid and synthetic drug candidates aspiring to achieve milestones like those set by Epidiolex, Marinol, Syndros, and Cesamet. Join 60+ experts from discovery, preclinical, translational, regulatory, clinical, and chemistry fields at the 7th CB1, CB2, and Cannabinoid Drug Development Summit as they work to unlock the potential of CB1, CB2, and cannabinoid drugs for treating obesity, pain, inflammation, CNS disorders, and rare diseases.